La société Pep-Therapy et ses partenaires d’un consortium européen viennent d’obtenir un financement de 6 M€ d’Horizon 2020 pour un programme de R&D sur le mélanome uveal (UM Cure 2020), une maladie rare de l’œil.
A European consortium focusing on the treatment of uveal melanoma (UM) has just been awarded a Horizon 2020 grant of 6 million euros.
UM is a rare intraocular tumour with no effective treatment for the metastatic disease. The overall goal of the “UM Cure 2020” project, by increasing the knowledge in UM metastases, is to identify and validate at the preclinical level novel therapeutic approaches for their treatment, up to the initiation of UM-dedicated clinical trials sponsored by academia, biotech or pharma companies. For this purpose, the Consortium, led by Dr. Sergio Roman-Roman (Institut Curie, Paris), brings together the major experts of UM in both patient care and basic/translational/clinical research, and in particular several European Centres of Excellence in clinical Ocular Oncology, as well as the patient organisation Melanoma Patient Network Europe and the two biotech companies PamGene and PEP-Therapy with expertise in biomarkers and preclinical & early clinical development, respectively.
Further details on the UM Cure 2020 project will be available at project start, foreseen for the end of the year/beginning of next year, after the ongoing grant agreement preparation phase with the European Commission.